ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 191 filers reported holding ASCENDIS PHARMA A/S in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $397,127 | +59.1% | 4,241 | +51.7% | 0.08% | +83.3% |
Q2 2023 | $249,543 | +37.7% | 2,796 | +65.4% | 0.04% | +20.0% |
Q1 2023 | $181,202 | -12.2% | 1,690 | 0.0% | 0.04% | -12.5% |
Q4 2022 | $206,400 | +5.8% | 1,690 | -10.6% | 0.04% | +5.3% |
Q3 2022 | $195,000 | +10.8% | 1,890 | 0.0% | 0.04% | +8.6% |
Q2 2022 | $176,000 | -75.5% | 1,890 | -69.2% | 0.04% | -72.7% |
Q1 2022 | $719,000 | -12.8% | 6,129 | 0.0% | 0.13% | +3.2% |
Q4 2021 | $825,000 | -86.6% | 6,129 | -84.1% | 0.12% | -75.8% |
Q3 2021 | $6,160,000 | +1219.1% | 38,650 | +988.7% | 0.51% | +1247.4% |
Q2 2021 | $467,000 | +11.5% | 3,550 | +9.2% | 0.04% | +18.8% |
Q1 2021 | $419,000 | -27.4% | 3,250 | -89.5% | 0.03% | +14.3% |
Q1 2016 | $577,000 | +1.2% | 31,100 | 0.0% | 0.03% | +16.7% |
Q4 2015 | $570,000 | +3.6% | 31,100 | 0.0% | 0.02% | -4.0% |
Q3 2015 | $550,000 | -86.8% | 31,100 | -86.8% | 0.02% | -85.6% |
Q2 2015 | $4,165,000 | -67.2% | 235,560 | -67.8% | 0.17% | -63.9% |
Q1 2015 | $12,694,000 | – | 731,660 | – | 0.48% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |